Image Protect, Inc. Unveils Strategic Growth Vision with InterceptCS™ Cold Sore Prevention System
Image Protect, Inc. outlines its strategic growth vision and long-term revenue objectives centered on the InterceptCS™ Cold Sore Prevention System, targeting a significant market opportunity in the wellness technology space.
Image Protect, Inc. (OTC: IMTL) has shared an update on its strategic growth vision and long-term revenue goals, focusing on its InterceptCS™ Cold Sore Prevention System. The system, classified as a Class II Medical Device by Health Canada, represents a novel approach to preventing cold sores, addressing a global market estimated at over $3.5 billion annually.
The company is leveraging a multi-channel sales strategy, including direct-to-consumer ecommerce and partnerships with platforms like Amazon, to make InterceptCS™ widely accessible. With a long-term revenue target of up to $100 million annually, Image Protect is banking on the device's unique positioning and the recurring revenue model from thermal activator sales.
Marketing efforts are comprehensive, spanning social media campaigns, paid advertising, and influencer outreach, aimed at building brand awareness and driving customer acquisition. CEO Frank Casella highlighted the potential of InterceptCS™ to meet the needs of an estimated 49 million cold sore sufferers in North America, emphasizing the product's preventative benefits and the ongoing development of a more cost-effective thermal activator.
While the company is optimistic about its growth trajectory, it cautions that forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from projections.